IP Library Granted Patent US 9,845,482
Granted Patent B2
US 9,845,482 · App. 13/447,083 · Granted Dec 19, 2017

Compositions and methods for enhancing bioenergetic status in female germ cells

Inventors: Jonathan L. Tilly (Windham, NH); David A. Sinclair (Chestnut Hill, MA)
Assignees: The General Hospital Corporation; President and Fellows of Harvard College
C12N15/873A61K31/05A61K31/137A61K31/277A61K31/352A61K31/4745A61K31/498A61K35/14A61K35/28A61K35/51A61K35/54C07D213/50C07D233/60C07D233/88C07D277/36C07D277/587C07D277/64C07D495/04C12N5/0609C12N5/0682C12N2501/40C12N2517/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,845,482
App. No.
13/447,083
Granted
Dec 19, 2017
Kind
B2
Abstract

Compositions and methods comprising bioenergetic agents for restoring the quality of aged oocytes, enhancing oogonial stem cells or improving derivatives thereof (e.g., cytoplasm or isolated mitochondria) for use in fertility-enhancing procedures, are described.

Claims (18)

1. A method of culturing a mammalian oocyte, a mammalian oogonial stem cell (OSC), the progeny of a mammalian OSC or a mammalian preimplantation zygote, wherein the OSC is obtained from ovarian tissue, is an isolated non-embryonic stem cell, and is mitotically competent and expresses Vasa, Oct-4, Dazl and Stella and, optionally, a stage-specific embryonic antigen, said method comprising:

culturing said oocyte, OSC, progeny of an OSC or preimplantation zygote in a medium comprising a CD38 inhibitor and a nicotinamide adenine dinucleotide (NAD) precursor,

wherein the CD38 inhibitor is a compound selected from the group consisting of apigenin, luteolin, tyrphostin-8, berberine and SRT-1720,

wherein the NAD precursor is a compound selected from the group consisting of nicotinamide, mononucleotide, nicotinamide riboside or nicotinic acid, and

wherein the CD38 inhibitor and the NAD precursor are present in the medium in an amount effective to enhance the bioenergetic status of said oocyte, OSC, progeny of an OSC or preimplantation zygote cultured in said medium.

2. The method of claim 1 , wherein the medium is selected from the group consisting of cell culture medium, oocyte retrieval solution, oocyte washing solution, oocyte in vitro maturation medium, ovarian follicle in vitro maturation medium, oocyte in vitro fertilization medium, vitrification solution and cryopreservation solution.

3. The method of claim 1 , wherein the NAD precursor is nicotinamide riboside.

4. The method of claim 1 , wherein the NAD precursor is nicotinic acid.

5. The method of claim 1 , wherein a mammalian OSC is cultured.

6. The method of claim 1 , wherein the mammalian oocyte, or OSC, progeny of an OSC or preimplantation zygote is from a human female.

7. The method of claim 6 , wherein the human female is selected from the group consisting of females of advanced maternal age, females suffering from oocyte-related infertility and females with low ovarian reserve.

8. The method of claim 1 , wherein the CD38 inhibitor and the NAD precursor are present in the medium in an amount effective to increase the number of functional mitochondria in the mammalian oocyte, OSC, progeny of an OSC or preimplantation zygote cultured in said medium.

9. The method of claim 1 , wherein the CD38 inhibitor and the NAD precursor are present in the medium in an amount effective to increase the mitochondrial energy of the mammalian oocyte, OSC, progeny of an OSC or preimplantation zygote cultured in said medium.

10. The method of claim 1 , wherein the CD38 inhibitor and the NAD precursor are present in the medium in an amount effective to increase the cellular energy of the mammalian oocyte, OSC, progeny of an OSC or preimplantation zygote cultured in said medium.

11. The method of claim 1 , wherein the CD38 inhibitor is present at a concentration ≧25 μM.

12. The method of claim 1 , wherein the NAD precursor is present at a concentration ≧100 μM.

13. The method of claim 1 , wherein the medium further comprises ovarian tissue, ovarian follicles, bone marrow, umbilical cord blood or peripheral blood.

14. The method of claim 1 , wherein the mammalian OSC expresses a stage-specific embryonic antigen.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jan 22, 2013
From: THE GENERAL HOSPITAL CORPORATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029668/0531 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2012
From: TILLY, JONATHAN L.
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 028301/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2012
From: SINCLAIR, DAVID A.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 028301/0949 →
Continuity (3)
Provisional Application 61502840 · Jun 29, 2011
Provisional Application 61600529 · Feb 17, 2012
Related Publication 20130059384A1 · Mar 7, 2013